Not sure how to proceed with a result like this. Confusing. No clear direction from my doctor…..
HISTORY: Prostate specific antigen above reference range R97.20: Elevated prostate specific antigen (PSA)
COMPARISON: None.
TECHNIQUE: Multiplanar multisequence MR imaging of the pelvis performed without and with intravenous contrast using the prostate protocol. Multiple B-value diffusion-weighted imaging in the axial plane was also performed through the prostate gland with
ADC mapping.
IV Gadavist 10 mL.
FINDINGS:
PROSTATE VOLUME: 6.8 x 4.29 x 6.1 cm with a prostate volume 95 mL.
PERIPHERAL ZONE: Diffuse abnormality of the peripheral zone noted characterized by low T2-weighted signal and mildly elevated diffusion-weighted signal and mildly decreased ADC signal without focal lesions. The capsule is well defined.
TRANSITION/CENTRAL ZONE: Diffuse nodular transition zone noted
OTHER PELVIS: No pelvic adenopathy identified. The seminal vesicles appear symmetric. The bladder appears normal.
Impression
IMPRESSION:
1. Diffuse abnormality the peripheral zone. This is a nonspecific finding and can be seen in both acute and chronic prostatitis or other inflammatory process and rarely in diffuse malignancy. Malignancy being considered less likely in the presence of
a well-defined capsule. Consider follow-up MRI in 6 months.
FINAL PI-RADS: 3, intermediate. The presence of clinically significant cancer is equivocal.
Your initial question indicated that a PIRADS 5 lesion was found, but I didn’t see that mentioned in the MRI report you posted.
Was a PIRADS 5 mentioned elsewhere…there’s a significant difference between a PIRADS 3 and a PIRADS 5.
Why are you saying: “No clear direction from my doctor…..”?
I would also be asking:
1) About the possibility of prostatitis?
2) What has been your PSA trend…has your 8.6 been stable, recently rising, or brand new….prior PSA values matter.
3) What is your family history of prostate cancer?
4) Have you had a digital rectal exam (DRE), if so what was the result?
More questions to ask your doctor….
Best,
Alan